Recent Updates
Recently added Catalysts

Cadrenal Therapeutics, Inc.

CVKDFDA catalysts, PDUFA dates & pipeline intelligence
$1.7
▲ +0.01 · +0.59%

Financials

Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Quarterly Cash
Unlock full CVKD financials and dilution scoring
Quarter by quarter figures, cash trend and dilution risk.
Institutional-grade data · Cancel anytime
52W LOW $0.8252W HIGH $12.50
Volume
206.73 K
Value Traded
348.41 K
Short % Float
6.2%
Days to Cover
3.5
+12.58%Week
+66.67%1 Month
+5.59%3 Month
-67.24%6 Month
-84.96%1 Year
-97.25%All Time

Cash Data

Unlock CVKD cash and runway
  • Monthly Burn
  • Burn Trend
  • Dilution Risk
  • SEC Filing

Key Stats

Market Cap
7.01 M
EPS (TTM)
-3.48
P/E Ratio
-
Ent. Value
3.95 M
Total Shares
4.12 M
Float Shares
3.72 M
Insiders
9.66%
Institutions
10.41%

Upcoming Catalysts

FDA decisions, readouts and PDUFA dates · scored by probability of approval

Catalyst Drug / Treatment Stage Prob. of Approval Description Drug Type Therapeutic Area Source
NDA Submission
CAD-1005 (first-in-class 12-lipoxygenase inhibitor)
Heparin-induced thrombocytopenia (HIT)
Fast TrackOrphan
NDASmall MoleculesHematology
Unlock every CVKD catalyst date and PoA score
Every FDA decision, readout and PDUFA date, with drug type, therapeutic area and a PoA score you can trade on.
Institutional-grade data · Cancel anytime
PoA blends historical approval base rates, trial design score and FDA review track record.

CVKD Catalyst Timeline

Dated clinical, regulatory and corporate events for Cadrenal Therapeutics, Inc.

Catalyst Timeline

Dated clinical, regulatory & corporate events for Cadrenal Therapeutics, Inc.

119Total events
5Upcoming
29Tier-1 (high impact)
2023 to 2029Coverage

Upcoming catalysts 2

T2Runway Guidance Update
Subscribe to view catalyst details
T1NDA Submission
Subscribe to view catalyst details
CAD-1005

Event history 50

●Timing GuidancePresentation
Board initiates formal strategic process to evaluate value-maximizing transactions
●Partnership / LicenseCorporate
Engaged Tungsten Advisors as exclusive strategic financial advisor
●Rare Pediatric DiseasetecarfarinDesignation
Submitted request to FDA for Rare Pediatric Disease Designation for tecarfarin
Prevention of the Formation of Life-Threatening Blood Clots Inside Coronary Artery Aneurysms in Children with Kawasaki Diseasesource ↗
●R&D DayPresentation
Cadrenal management one-on-one meetings at Lytham Partners Fall 2026 Investor Conference
▲FDA Feedback ReceivedCAD-1005FDA Meeting
Positive feedback from FDA Type D meeting announced
heparin-induced thrombocytopeniasource ↗
▲Partnership / LicenseCorporate
Signed agreement with global firm for non-dilutive funding
▼Equity OfferingCorporate
Private placement generating approximately $3.0 million in gross proceeds
●Quarterly UpdateCorporate
Reported Q2 2026 financial results
▲FDA Feedback ReceivedCAD-1005FDA Meeting
Achieved regulatory guidance on Phase 3 path for CAD-1005
heparin-induced thrombocytopenia (HIT)source ↗
▲Type D MeetingCAD-1005FDA Meeting
FDA Type D Meeting held on July 28, 2026
heparin-induced thrombocytopeniasource ↗
Unlock the full CVKD catalyst timeline
Every PDUFA date, readout, approval and corporate move, tiered by market impact and updated daily.
Institutional-grade data · Cancel anytime

Past FDA Catalysts and PDUFA Decisions

How CVKD actually traded into and out of each decision

Date Drug Catalyst Stage Reaction Event Move % Best Trade %
2026-09-11CAD-1005 Phase 2 data presentation Phase 2
Unlock 1 more CVKD historical catalyst
Institutional-grade data · Cancel anytime
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision

Drug Pipeline Intelligence

Pipeline Score
Pipeline Value
Valuation Signal
1
Drugs Scored
rNPV / MCap
Top Drug
Top 91%
Micro Cap
(rank 654 of 719)
Percentile Rank
Showing 1 of 2 assets
DrugIndicationPhasePTRSrNPVStatusEnrollVelocityDesignEst. CompletionML SignalLast Change
VLX-1005 Small MoleculesCompletedNCT05325346Heparin-induced ThrombocytopeniaPhase 1 COMPLETED 12Apr 14, 2022
Unlock the CVKD pipeline intelligence model
PTRS, rNPV, enrollment velocity, trial design quality and ML risk signals for every asset above.
Institutional-grade data · Cancel anytime

Clinical Trial Results

Readouts, endpoints and source filings for every CVKD program

Drug Name Indication Phase Date Trial Results SummaryTitleSource
CAD-1005
Fast TrackOrphan
Heparin-Induced Thrombocytopenia (HIT) and Cardiac Surgery-Associated Acute Kidney Injury (CSA-AKI)Phase 22026-08-03greater than 25%Read MoreCadrenal Therapeutics Solidifies Multi-Indication Strategy for CAD-1005 in Cardiac Acute Critical Care Following Competitor’s Phase 3 DiscontinuationRead More
Scroll for more · summaries link to the source press release
Unlock every CVKD trial readout
Institutional-grade data · Cancel anytime

Inside Trades

Unlock CVKD insider buying and selling
Monthly insider buys and sells against the stock price, with the insider sentiment reading.
Institutional-grade data · Cancel anytime
InsiderSideSharesPriceValueDate
Pham Quang XDirector, Officer (Chairman and CEO), 10% OwnerSell -7,400 98,589 held$3.03 06/29/2026
Unlock the full CVKD insider trade log
Institutional-grade data · Cancel anytime

Hedge Fund 13F Activity

Fund % of Portfolio Current MV Shares Owned Activity
No hedge fund reported a 13F position in CVKD for Q3 2026.
Unlock every fund holding CVKD
Every 13F position with quarter over quarter share flow and average entry price.
Institutional-grade data · Cancel anytime
Unlock hedge fund flows in CVKD
Shares held by hedge funds each quarter, and who bought or sold.

Ownership Trends

Sign in to see CVKD ownership
Insider and institutional ownership, quarter by quarter.

CVKD Short Interest

Shares sold short, counted twice a month.

6.2%
Short % of Float
of tradable shares sold short
230.7K
Shares Sold Short
-18.0% vs prior count
3.5 Moderate
Days to Cover
trading days of normal volume to buy every short share back
66.3K
Avg Daily Volume
the average used for days to cover
Unlock CVKD short interest history
Two years of days to cover and shares sold short, with every count and its change.
Institutional-grade data · Cancel anytime

Options Data

Option Volume

Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg

Option Chain Statistics

ExpiryCall VolPut VolVol P/CCall OIPut OIOI P/CIV CallIV Call OI-WtdIV Call Vol-WtdIV PutIV Put OI-WtdIV Put Vol-Wtd
Unlock CVKD option chain statistics
Per-expiry call and put volume, open interest, put-call ratios and implied volatility.
Institutional-grade data · Cancel anytime

Real-Time Option Chain

CallsStrikePuts
LastVolOILastVolOI
No data available
Unlock the live CVKD option chain
Live calls and puts by strike: last price, volume and open interest for every expiry.
Institutional-grade data · Cancel anytime

Calls vs Puts by Expiry

CallsPutsLog scale
Unlock CVKD options analytics
Institutional-grade data · Cancel anytime

Competitive positioning

How CVKD ranks across every disease it competes in

Competitive Position is a premium feature
See how CVKD ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial

CVKD News

CVKD
Oct 7, 2026
CVKDGeneral

Cadrenal Therapeutics Retains Tungsten Advisors to Lead Formal Strategic Process to Maximize Value of its Orphan Thrombo-Inflammatory Therapeutics

Cadrenal Therapeutics has initiated a formal strategic process to explore opportunities for maximizing the value of its assets, including CAD-1005, following alignment with the FDA on its Phase 3 development pathway. The company has engaged Tungsten Advisors as its exclusive financial advisor and has received significant interest from potential partners. However, there is no guarantee that this process will result in any transactions.

Read more →
CVKD
Sep 21, 2026
CVKDConferences/Events

Cadrenal Therapeutics to Participate in the Lytham Partners Fall 2026 Investor Conference

Cadrenal Therapeutics, Inc. will participate in the Lytham Partners Fall 2026 Investor Conference on September 29-30, 2026. CEO Quang X. Pham will present via webcast and hold one-on-one meetings with investors. The company focuses on therapies for critical care cardiology and has a promising pipeline, including CAD-1005 and tecarfarin, both of which have received FDA designations.

Read more →
CVKD
Sep 3, 2026
CVKDConferences/Events

Cadrenal Therapeutics to Participate in H.C. Wainwright's 28th Annual Global Investment Conference

Cadrenal Therapeutics, Inc. will participate in the 28th Annual H.C. Wainwright Global Investment Conference from September 14-16, 2026. CEO Quang X. Pham will present on the company's Cardiac Acute Critical Care Franchise and recent Phase 2 clinical data for CAD-1005. A pre-recorded presentation will be available starting September 11, 2026.

Read more →
CVKD
Aug 31, 2026
CVKDFDA Updates
▲ +13.6%on this newsshared move

Cadrenal Therapeutics Announces Positive Outcome from FDA Type D Meeting for Phase 3 Registration Study of CAD-1005 in Heparin-Induced Thrombocytopenia

Cadrenal Therapeutics received positive feedback from the FDA during a Type D meeting regarding the Phase 3 registration study of CAD-1005 for treating heparin-induced thrombocytopenia (HIT). The FDA agreed on the primary endpoint and statistical analysis plan, which aims to evaluate the drug's effectiveness in reducing thrombotic events. CAD-1005 is positioned to target an unmet need in a significant patient population, with a projected revenue opportunity of $2 billion.

Read more →
CVKD
Aug 13, 2026
CVKDGeneral

Cadrenal Therapeutics Reports Second Quarter 2026 Financial Results; Provides a Corporate Update on the Cardiac Acute Critical Care Franchise and the Strategic Partnering Process

Cadrenal Therapeutics reported its Q2 2026 financial results and updates on its Cardiac Acute Critical Care Franchise. The company achieved regulatory guidance for CAD-1005's Phase 3 path and presented promising Phase 2 data at an international congress. Cadrenal is pursuing a structured partnering process to enhance its portfolio and address unmet needs in critical care cardiology.

Read more →
CVKD
Aug 3, 2026
CVKDPhases

Cadrenal Therapeutics Solidifies Multi-Indication Strategy for CAD-1005 in Cardiac Acute Critical Care Following Competitor’s Phase 3 Discontinuation

Cadrenal Therapeutics has consolidated its strategy for CAD-1005, targeting both Heparin-Induced Thrombocytopenia (HIT) and Cardiac Surgery-Associated Acute Kidney Injury (CSA-AKI). This move follows the discontinuation of a competitor's Phase 3 trial, highlighting the urgent need for novel treatments in this area. CAD-1005 has shown promising clinical data, positioning it as a first-in-class therapy in a lucrative market.

Read more →
CVKD
Jul 21, 2026
CVKDGeneral

Cadrenal Therapeutics Launches Partnering Process as Its Cardiac Acute Critical Care Assets Advance to Transaction Readiness Following Landmark ISTH Data Presentation

Cadrenal Therapeutics has initiated a partnering process for its cardiac acute critical care assets, including CAD-1005, frunexian, and tecarfarin. The company aims to secure strategic partnerships for these late-stage therapies following positive Phase 2 data presented at the ISTH 2026 Congress. This strategic alignment is designed to maximize asset value and address unmet needs in critical care cardiology.

Read more →
CVKD
Jul 13, 2026
CVKDPhases
▼ -16.3%on this news

Cadrenal Therapeutics’ Late-Breaking Phase 2 Data Demonstrate Greater Than 25% Reduction in Thrombotic Events in HIT for First-in-Class 12-LOX Inhibitor CAD-1005 at ISTH 2026 Congress

Cadrenal Therapeutics presented late-breaking Phase 2 data for CAD-1005 at the ISTH 2026 Congress, showing over a 25% reduction in thrombotic events in patients with Heparin-Induced Thrombocytopenia (HIT). This trial is notable as the first randomized, blinded, placebo-controlled study in this area. The results support the advancement of CAD-1005 towards Phase 3 trials, addressing a significant medical need.

Read more →
CVKD
Jul 1, 2026
CVKDGeneral
▼ -5.1%on this news

Cadrenal Therapeutics Announces up to $8.8 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Cadrenal Therapeutics has announced a private placement of up to $8.8 million, with $3 million upfront and potential additional proceeds from warrants. The funds are expected to extend the company's cash runway into 2027, allowing for the advancement of therapies for Kawasaki Disease and other conditions. The offering is set to close on July 1, 2026, pending customary conditions.

Read more →
CVKD
Jun 24, 2026
CVKDConferences/Events

Cadrenal Therapeutics Announces Selection of CAD-1005 Phase 2 Study for Late-Breaking Oral Presentation at ISTH 2026 Congress

Cadrenal Therapeutics announced that its Phase 2 study of CAD-1005 has been selected for a late-breaking oral presentation at the ISTH 2026 Congress. This trial is the first randomized, blinded, placebo-controlled study for Heparin-Induced Thrombocytopenia (HIT), a serious blood-clotting disorder. The presentation will highlight the clinical potential of CAD-1005, a novel 12-lipoxygenase inhibitor, which could transform treatment for HIT patients.

Read more →
CVKD
Jun 18, 2026
CVKDFDA Updates
▲ +12.9%on this newsshared move

Cadrenal Therapeutics to File for FDA Rare Pediatric Disease Designation for Tecarfarin in Kawasaki Disease

Cadrenal Therapeutics is preparing to file for a Rare Pediatric Disease Designation for tecarfarin, aimed at treating Kawasaki disease in children. This designation could lead to a Priority Review Voucher, enhancing the drug's market potential. The company will showcase its initiatives at the upcoming BIO International Convention, highlighting its Phase 3-ready pipeline.

Read more →
CVKD
Jun 15, 2026
CVKDPhases
▼ -10%on this newsshared move

Cadrenal Therapeutics Advances Multi-Indication Strategy for CAD-1005; Launches Phase 2a Acute Kidney Injury (CSA-AKI) Clinical Plan to Accelerate Pharma Partnering at Upcoming BIO 2026

Cadrenal Therapeutics announced plans to initiate a Phase 2a clinical trial for CAD-1005, targeting Cardiac Surgery-Associated Acute Kidney Injury (CSA-AKI). This indication expands the drug's potential market, estimated at $1 billion annually, as there are currently no FDA-approved therapies for CSA-AKI. The trial aims to generate safety and efficacy data while leveraging existing research on CAD-1005's use in heparin-induced thrombocytopenia (HIT). Discussions about this strategy will take place at the upcoming BIO 2026 conference.

Read more →
CVKD
Jun 3, 2026
CVKDConferences/Events

Cadrenal Therapeutics to Showcase Phase 3-Ready CAD-1005 and Novel 12-LOX Platform at BIO International Convention 2026 Partnering Event

Cadrenal Therapeutics is set to showcase its Phase 3-ready CAD-1005 and 12-LOX platform at the BIO International Convention 2026. CAD-1005 targets Heparin-Induced Thrombocytopenia (HIT) and has received FDA designations for its potential to address unmet medical needs. The company aims to explore broader applications for its 12-LOX inhibitor platform, which may impact various inflammatory diseases. Tecarfarin, another late-stage product, is designed for patients with complex anticoagulation needs.

Read more →
CVKD
May 19, 2026
CVKDConferences/Events

Cadrenal Therapeutics to Participate in the Lytham Partners Spring 2026 Investor Conference on May 28, 2026

Cadrenal Therapeutics, Inc. will participate in the Lytham Partners Spring 2026 Investor Conference on May 28, 2026. The company will host a webcast presentation and one-on-one meetings with investors. Cadrenal is focused on developing therapies for immune and thrombotic conditions, including its lead program CAD-1005, which targets heparin-induced thrombocytopenia.

Read more →
CVKD
May 7, 2026
CVKDPhases

Cadrenal Therapeutics Reports First Quarter 2026 Financial Results and Provides Phase 3 Development Update on CAD-1005 Following End-of-Phase 2 Meeting with FDA

Cadrenal Therapeutics reported its financial results for the first quarter of 2026 and updated on the development of CAD-1005, a treatment for heparin-induced thrombocytopenia (HIT). The company has received FDA guidance following their End-of-Phase 2 meeting, which outlines the path for a pivotal Phase 3 trial. Cadrenal plans to move directly to a randomized, placebo-controlled study, building confidence that CAD-1005 could become the first new therapy for HIT in over 20 years. Financially, the company experienced reduced operating expenses but reported a net loss of $2.5 million.

Read more →
CVKD
Apr 30, 2026
CVKDPhases
▲ +19.3%on this newsshared move

Cadrenal Therapeutics Announces End-of-Phase 2 Meeting with the FDA and Pivotal Phase 3 Registration Path for CAD-1005 in Heparin-Induced Thrombocytopenia (HIT)

Cadrenal Therapeutics has announced a significant regulatory milestone following its successful End-of-Phase 2 meeting with the FDA regarding CAD-1005, aimed at treating heparin-induced thrombocytopenia (HIT). The FDA provided essential guidance for Cadrenal's plan to move forward with a pivotal Phase 3 registration study, which will evaluate CAD-1005 in around 120 patients globally. The Phase 3 study intends to support a new drug application by 2029, marking CAD-1005 as a potential groundbreaking therapy for HIT, which has not seen new treatment options in decades.

Read more →
CVKD
Mar 31, 2026
CVKDPhases
▲ +20.5%on this newsshared move

Cadrenal Therapeutics Reports Fourth Quarter 2025 Financial Results; Provides Corporate Update on CAD-1005 Program for HIT Following End-of-Phase 2 FDA Meeting

Cadrenal Therapeutics has reported its fourth quarter 2025 financial results along with an update on its CAD-1005 program for heparin-induced thrombocytopenia (HIT). The company revealed that encouraging Phase 2 data supports continued development of CAD-1005 as a priority, following a successful End-of-Phase 2 meeting with the FDA. Although the company is experiencing financial losses, the progress in clinical development and FDA collaboration signifies potential advancements in treatment for HIT.

Read more →
CVKD
Mar 12, 2026
CVKDPhases
▼ -7.9%on this news

Cadrenal Therapeutics Highlights Research Supporting 12-LOX Inhibition in Reducing

Cadrenal Therapeutics has announced promising research highlighting the potential of its first-in-class 12-lipoxygenase (12-LOX) inhibitor, CAD-1005, in reducing inflammation associated with obesity and Type 2 diabetes. The findings suggest that 12-LOX inhibition may improve glucose homeostasis and peripheral inflammation. Additionally, CAD-1005 has shown significant benefits in preclinical models and has been successful in a Phase 2 trial for treating Heparin-Induced Thrombocytopenia (HIT). The company aims to explore further applications of 12-LOX inhibition in various inflammatory conditions.

Read more →
CVKD
Mar 2, 2026
CVKDPhases

Cadrenal Therapeutics Highlights Recent 12-LOX Inhibitor Platform Expansion

Cadrenal Therapeutics announced promising results from a Phase 2 study of CAD-1005, a selective 12-LOX inhibitor for heparin-induced thrombocytopenia (HIT). The company plans to hold an End-of-Phase 2 meeting with the FDA soon. Additionally, the acquisition of a 12-LOX inhibitor portfolio opens avenues for treating various inflammatory and thrombotic conditions, potentially addressing significant market needs.

Read more →
CVKD
Feb 24, 2026
CVKDPhases
▲ +16.1%on this news· ran to +29% by day 1

Cadrenal Therapeutics Announces Phase 2 Results with Encouraging Reductions in Thrombotic Events for CAD-1005 in HIT, Supporting Clinical Advancement

Cadrenal Therapeutics announced positive Phase 2 trial results for CAD-1005 in patients with heparin-induced thrombocytopenia (HIT), showing a greater than 25% reduction in thrombotic events compared to placebo. Although the primary endpoint of platelet count recovery was not met, the secondary endpoint results were encouraging. An End-of-Phase 2 meeting with the FDA is scheduled to discuss the path forward for Phase 3 trials.

Read more →

About Cadrenal Therapeutics, Inc.

Ponte Vedra, FL 5 employees cadrenal.com
Headquarters822 A1A NORTH, PONTE VEDRA, FL, 32082
BIOPHARMAWATCH ELITE
Trade the next CVKD catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $24/mo billed annually.
Cancel anytime